Interferon-gamma and TNF-alpha synergistically enhance the immunomodulatory capacity of Endometrial-Derived Mesenchymal Stromal Cell secretomes by differential microRNA and extracellular vesicle release

María de los Ángeles de Pedro^{1†}, Federica Marinaro¹, Esther López^{1*}, María Pulido¹, Francisco Miguel Sánchez-Margallo^{2,3*}, Verónica Álvarez¹, Javier G Casado^{1,2}

¹Stem Cell Therapy Unit, Jesús Usón Minimally Invasive Surgery Centre, Cáceres, Spain

²CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain

³Scientific Direction, Jesús Usón Minimally Invasive Surgery Centre, Cáceres, Spain

Corresponding author: Esther López (elopez@ccmijesususon.com)

Abstract

Endometrial Mesenchymal Stromal Cells (endMSCs) can be easily isolated from menstrual blood by plastic adherence. These cells have a potent pro-angiogenic and immunomodulatory capacity, and their therapeutic effect is mediated by paracrine mechanisms where secretome have a key role. In this paper, we aimed to evaluate different priming conditions in endMSCs using pro-inflammatory cytokines and Toll-Like Receptor ligands. Our *in vitro* results revealed a synergistic and additive effect of IFN γ and TNF α on endMSCs. The combination of these pro-inflammatory cytokines significantly increased the release of Indoleamine 2,3-dioxygenase (IDO1) in endMSCs. Additionally, this study was focused on the phenotype of IFN γ /TNF α -primed endMSCs (endMSCs*). Here we found that immune system-related molecules such as CD49d, CD49e, CD54, CD56, CD58, CD63, CD126, CD152, or CD274 were significantly altered in endMSCs* when compared to control cells. Afterward, our study was completed with the characterization of released miRNAs by Next Generation Sequencing (NGS). Briefly, our system biology approaches demonstrated that endMSCs* showed an increased release of 25 miRNAs whose target genes were involved in immune response and inflammation. Finally, the cellular and molecular characterization was completed with *in vitro* functional assays.

In summary, the relevance of our results lies in the therapeutic potential of endMSCs*. The differences in cell surface molecules involved in migration, adhesion and immunogenicity, allowed us to hypothesize that endMSCs* may have an optimal homing and migration capacity towards inflammatory lesions. Secondly, the analysis of miRNAs, target genes and the subsequent lymphocyte activation assays demonstrated that IFN γ /TNF α -primed secretome may exert a potent effect on the regulation of adverse inflammatory reactions.

Introduction

Mesenchymal stromal cells (MSCs) are multipotent fibroblast-like plastic-adherent cells (1) that can be isolated from various pre- and post-natal tissues (2), being the endometrium among them. Endometrial-derived MSCs (hereinafter referred to as endMSCs) can be isolated from biopsies containing the endometrial *stratum functionalis* and *stratum basalis*, or from menstrual fluid (3). These cells can be further purified by plastic adherence and *in vitro* expanded using standard culture conditions (4). The scientific literature has also described different stem/progenitor cells in the three tissue layers of endometrium (5–7) and how to isolate them using different procedures (8–10). Isolation from menstrual blood is a non-invasive and reproducible method (5) that allows the retrieval of MSCs fulfilling the minimal criteria proposed by the International Society of Cellular Therapy. Firstly, they have plastic adherence in tissue culture. Secondly, they display a CD105+, CD73+, CD90+, CD45-, CD34-, CD14-, and HLA-DR- phenotype. Third, they possess an *in vitro* differentiation capacity towards osteoblasts, adipocytes and chondroblasts (11).

MSCs have well-known immunomodulatory and regenerative properties (12), being used in preclinical and clinical trials (13). Moreover, these endMSCs have also demonstrated an immunosuppressive activity (14–16), as well as anti-apoptotic and pro-angiogenic capacities (17) which are mediated by paracrine factors. In this paracrine activity, secretome is necessary for intercellular communication and comprise extracellular vesicles (EVs), exosomes, proteins, nucleic acids, and lipids with therapeutic potential.

Many strategies to improve the regenerative effects and efficacy of secretome components have been recently proposed and reviewed (18,19). Basically, the main idea is to optimize *in vitro* culture conditions and provide stimuli (the so-called “priming” or “licensing”) to use MSCs as “cell factories”. In this process, the “manufactured products” are therapeutically bioactive vesicles. Nowadays, most of the priming strategies have been optimized using MSCs derived from bone marrow, from umbilical cord, or adipose tissue (19). These priming strategies have been evaluated using different cytokines, such as IL17A, IL1 β , FGF2, TNF α , and IFN γ (20–24); different molecules, such as LL37, Lipopolysaccharide (LPS), Polyinosinic: polycytidylic acid (Poly (I:C)), curcumin, oxytocin, and melatonin (25–28); different chemical agents such as 5-aza-2'-deoxycytidine, valproic acid, and sphingosine-1-phosphate (29–31); and different hypoxia conditions (32–36). Additionally, all these priming strategies have been combined and optimized using different concentrations of the priming agent. For example, LPS has been used in combination with TNF α (21) or Poly(I:C) in MSCs with effects on cytokine secretion (37).

There are plenty of studies focused on the MSC-priming strategy with very different purposes: induction of angiogenesis, regeneration, or cell viability. In this study, we have evaluated different priming strategies to enhance the immunomodulatory capacity of secretomes from endMSCs. Moreover, the immunomodulatory effect of their secreted vesicles has already been demonstrated by our group (38), and additional studies allowed us to understand, at least in part, the complexity of the molecular networks and their effects on target cells (39).

There are several publications focused on the analysis of IFN γ - and TNF α -primed cells. In two of them, authors demonstrated an upregulation of indoleamine 2,3-dioxygenase (IDO1) (40), which is mediated by chromatin remodeling at the *IDO1* promoter (41). Moreover, an inhibition of

complement activation by factor H has been described (42). It is important to note that these publications analyzed the effect of priming upon cells, but not upon the secreted vesicles.

On the other hand, priming strategies using IFN γ and TNF α have also been widely studied for secretome based therapies. Here we summarize some studies focused on the analysis of secretomes by IFN γ /TNF α -primed MSCs. In the case of IFN γ , EVs from IFN γ -primed MSCs have been found to enhance macrophage bacterial phagocytosis (43) and membrane particles obtained from IFN γ -primed MSCs can induce an increase of anti-inflammatory PD-L1 monocytes (44). In the case of TNF α , EVs from TNF α -primed MSCs showed a therapeutic effect in urethral fibrosis (45), an improvement in the proliferation and differentiation of osteoblasts (46), as well as neuroprotective effects (47). In the case of priming strategies using the combinations of IFN γ /TNF α , *in vitro* studies have revealed that IFN γ /TNF α -primed MSCs produced EVs with a heightened immunomodulatory potential due to prostaglandin E2 and cyclooxygenase 2 pathway alteration (48). Priming MSCs with IFN γ /TNF α also shifted macrophages polarization from M1 to M2 by miRNAs (49) and resulted in immunomodulatory EVs which induced M2 differentiation and enhancement of Tregs (50). All these studies suggest that IFN γ and TNF α have an enormous potentiality to act as priming agents for MSCs.

According to our previous studies (38,39) and considering all preceding findings in different MSCs, the aim of this study was to evaluate different priming strategies in endMSCs. Our results firstly revealed a synergistic and additive effect of IFN γ and TNF α that significantly triggered the release of IDO1. Secondly, these cytokines significantly contributed to phenotypic changes in molecules involved in migration, adhesion, and immunogenicity. Third, IFN γ /TNF α -primed endMSCs (endMSCs*) deliver miRNAs which target inflammation-related genes. Finally, *in vitro* functional assays have demonstrated the immunomodulatory capacity of these vesicles.

To our knowledge, this is the first report focused on the optimization of priming strategies in endMSCs. Our results have demonstrated that IFN γ /TNF α priming have a profound impact on the immunomodulatory potential of released vesicles and miRNAs profile of these secretomes, as well as in the migration/adhesion capacity of these cells. Altogether, these results may have clinical implications for the therapeutic use of secretomes in inflammatory mediated-diseases.

Material and Methods

Isolation, culture, and characterization of human endMSCs

A summary of all the experimental procedures is shown in Figure 1. Written informed consent was obtained from human menstrual blood donors and approved by the Ethics Committee of the Jesús Usón Minimally Invasive Surgery Center. Human menstrual blood samples were collected by three healthy pre-menopausal women and endMSCs were isolated under sterile conditions according to a previously described protocol (38). Following a 1:2 dilution and homogenization of the menstrual blood in phosphate buffered saline (PBS), a first centrifugation at 450 $\times$ g for 10 min was carried out. The pelleted cells were recovered and seeded in Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific, Bremen, Germany), 1% penicillin/streptomycin, and 1% glutamine, at 37 °C and 5% CO $_2$. The adherent endMSCs were cultured to 80% confluency, onto tissue culture flasks, while the non-adherent cells were discarded

after 24 h. The cell culture medium was replaced every 3 or 4 days. The cells were detached from tissue culture flasks using PBS containing 0.25% trypsin (Lonza, Gaithersburg, MD, USA). The isolated endMSCs were characterized by flow cytometry and differentiation assay, as in our previous studies (38,39,51).

Priming of endMSCs and IDO1 quantification by ELISA

Different lineages of *in vitro* cultured endMSCs (n = 3) were primed using a combination of recombinant pro-inflammatory cytokines and Toll-like receptors (TLR) ligands: IFN γ (Miltenyi Biotec Inc, San Diego, CA, USA) at 1 ng/ml and 100 ng/ml, TNF α (Miltenyi Biotec Inc) at 1 ng/ml and 100 ng/ml, LPS (Sigma, St. Louis, MO, USA) at 1 ng/ml and Poly (I:C) (Miltenyi Biotec Inc) at 1 ng/ml. At day 3, supernatants from *in vitro* primed endMSCs were collected to evaluate the release of IDO1. According to the manufacturer's instructions, the IDO1 levels were quantified by ELISA (R&D SYSTEMS, Minneapolis, USA).

Phenotypic surface markers and comparison of endMSCs and endMSCs*

The phenotypic analysis of the cells was performed by flow cytometry using a panel of human monoclonal antibodies (Supplementary table 1). The endMSCs at passages 5–7 and 80% confluence, were *in vitro* cultured devoid of recombinant IFN γ and TNF α (endMSCs, n = 3) or with 100 ng/ml IFN γ and 100 ng/ml TNF α for 72 h (endMSCs*, n = 3). The endMSCs and endMSCs* were detached from tissue culture flasks using PBS containing 0.25% trypsin and incubated with different antibodies for 30 min at 4 °C in PBS with 2% of FBS. Cells were then washed, resuspended in PBS and acquired in a FACSCalibur™ cytometer (BD Biosciences, San Jose, CA, USA) equipped with CellQuest software (BD Biosciences). Detached cells were incubated with the Fluorescence Minus One Control (FMO control) to properly compensate the flow cytometry data. Mean fluorescence intensities (MFI) and standard deviations (SD) of positive and negative populations were taken into consideration to calculate the Stain Index (SI) as follows: $MFI(\text{positive population}) - MFI(\text{negative population}) / 2 \times SD(\text{negative population})$.

Phenotypic profiles of endMSCs and endMSCs* were compared. Significant differentially expressed proteins underwent enrichment and biological pathway analyses with Cytoscape (version 3.7.2) (52), which includes the Gene Ontology Resource¹ and the Reactome Pathway Database².

Isolation, purification, and quantification of Secretomes.

The endMSCs (n = 3) and endMSCs* (n = 3) (obtained as mentioned above) at passages 6–12 and 80% confluence were used for secretome collection. Cell culture medium (with or without IFN γ and TNF α) was replaced by DMEM, 1% penicillin/streptomycin, 1% glutamine and 1% insulin-transferrin-selenium (Thermo Fisher Scientific, MA, USA), after rinsing with PBS. Cells were then cultured during 72 h at 37 °C and 5% CO₂, conditioned media were collected for the concentration of

¹ <http://geneontology.org/>

² <https://reactome.org/>

secretomes. Cells were detached with trypsin and counted with Neubauer chamber. Viability was evaluated though Trypan blue staining (Thermo Scientific).

Condition media from endMSCs and endMSCs* were centrifuged first at $1000 \times g$ 10 min 4 °C, then at $5000 \times g$ 20 min 4 °C. Pellets were discarded and the supernatants were filtered through 0.45 µm and 0.22 µm mesh (Fisher Scientific, Leicestershire, UK) to eliminate dead cells and debris. To concentrate the condition media, up to 15 ml filtered supernatants were ultra-filtered through a 3 kDa MWCO Amicon® Ultra device (Merck-Millipore, MA, USA) by centrifugation at $4000 \times g$ for 1 h at 4 °C. The concentration of proteins from enriched secretomes was quantified by Bradford assay (Bio Rad Laboratories, Hercules, CA). Finally, the secretomes from endMSCs (S-endMSCs) and endMSCs* (S-endMSCs*) were stored at -20°C for further analyses.

miRNAs analysis by Next Generation Sequencing

miRNA sequencing experiments were performed at QIAGEN Genomic Services (Hilde, Germany). Total RNA was isolated from 1 ml of each concentrated sample, using the exoRNeasy Serum/Plasma Kit (QIAGEN) according to manufacturer's instructions. During the sample preparation, QC Spike-ins were added as quality control. A total of 5 µl of purified RNA tagged with adapters containing a Unique Molecular Index (UMIs) was converted into cDNA NGS libraries using the QIAseqmiRNA Library Kit (QIAGEN). cDNA was amplified in 22 cycles of PCR and purified. Library preparation QC was performed using Bioanalyzer 2100 (Agilent). Libraries were pooled in equimolar ratios, based on quality of the inserts and the concentration measurements. They were then quantified by quantitative polymerase chain reaction (qPCR) and sequenced on a NextSeq500/550 System (Illumina, San Diego, CA, USA) according to the manufacturer instructions. Raw data was converted to FASTQ files for each sample using the bcl2fastq software (Illumina, Inc.). Quality control of raw sequencing data was checked using the FastQCtool³. The data analyses, which included filtering, trimming, mapping, quantification, and normalization, were carried out using CLC Genomics Workbench (version 20.0.2) and CLC Genomics Server (version 20.0.2). The human genome version GRCh38 was used as a reference database to annotate the miRNAs. The read sets were aligned to the reference sequences from miRbase (version 22). The differential expression between S-endMSCs and S-endMSCs* was evaluated through the EDGE (Empirical analysis of Differential Gene Expression) analysis within the CLC bio.

Using Benjamini-Hochberg FDR corrected *p* values, differentially expressed miRNAs at significance level of .05 (FDR) were selected for unsupervised analysis (principal component analysis -PCA-, clustering, and heat map) using ClustVis (version 2.0)⁴. Enrichment analysis of these miRNAs was performed using miRNet (version 2.0)⁵ and TAM (version 2.0)⁶. Moreover, significantly overexpressed miRNAs in S-endMSCs* were submitted to a miRTargetLink⁷ analysis to determine

³<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>

⁴<https://biit.cs.ut.ee/clustvis/>

⁵<https://www.mirnet.ca/>

⁶<http://www.lirmed.com/tam2/>

⁷<https://ccb-web.cs.uni-saarland.de/mirtargetlink/>

the human target genes of these miRNAs. Results were filtered to strong experimental evidence. Only genes included into the Gene Ontology category of *Inflammation Response* (GO:0006954) were taken into consideration. Enrichment analysis of these genes was performed using FunRich: Functional Enrichment analysis tool (version 3.1.3) (53,54). Target genes were sub-classified in four categories: *Innate Immune Response* (GO:0045087), *Adaptive Immune Response* (GO:0002250), *Positive Regulation of Inflammatory Response* (GO:0050728), and *Negative Regulation of Inflammatory Response* (GO:0050729). The datasets discussed in this publication have been deposited in Sequence Read Archive (SRA) data with the accession number PRJNA664968⁸.

Immunomodulatory assays on *in vitro* stimulated peripheral blood lymphocytes

Human peripheral blood lymphocytes (PBLs) from a healthy donor were stimulated using the T Cell Activation/ Expansion Kit (MACS, Miltenyi Biotec, USA) according to manufacturer instructions. Briefly, PBLs in RPMI-1640 medium supplemented with T Cell Activation/ Expansion Kit and 10% FBS were cultured in U-bottom 96 wells plate at 4×10^5 cells per well. S-endMSCs and S-endMSCs* were added to PBLs at 20, 40, and 80 μ g/ml, in accordance with protein concentrations resulting from the Bradford assay. At day 3 and day 6, *in vitro* stimulated PBLs were analyzed by flow cytometry. PBLs without stimulation were used as negative control. *In vitro* stimulated PBLs without secretomes were used as positive controls. For flow cytometry analyses, PBLs were collected and incubated for 30 min at 4 °C with fluorescence-labeled human monoclonal antibodies against: CD4, CD8, CD45RA, and CD62L (BD Biosciences), in the presence of PBS containing 2% of FBS. Cells were then washed and resuspended in PBS. The flow cytometric analysis was performed on CD4+ T cells, and CD8+ T cells, and the percentage of gated CD45RA-/CD62L- cells allowed us to quantify the percentage of effector-memory cells.

Statistical analysis

Data were statistically analyzed with GraphPad Prim (version 8.0) using paired *t* test for variables with parametric distribution and Wilcoxon test for non-parametric data. The $p \leq .05$ were considered statistically significant.

Results

Characterization of *in vitro* isolated and expanded endMSCs

A more detailed description of endMSC characterization can be found in our previous studies (38,39,51). Briefly, our endMSCs were plastic-adherent when maintained in standard culture conditions and their differentiation toward the adipogenic, chondrogenic, and osteogenic lineages was demonstrated by specific staining. The phenotypic analysis of *in vitro* expanded endMSCs revealed a positive expression for the surface markers CD44/CD73/CD90/CD105, and negative for CD14/CD20/CD34/CD45/CD80/HLA-DR. The cell lines used for this study complied with the Minimal criteria for defining multipotent mesenchymal stromal cells (11).

⁸ <http://www.ncbi.nlm.nih.gov/bioproject/664968>

Effect of endMSCs priming on IDO1 release.

In order to enhance the immunomodulatory capacity of secretomes from endMSCs, different pro-inflammatory cytokines (TNF α , IFN γ) and TLR ligands (LPS, Poly (I:C)) were evaluated under *in vitro* conditions. The release of IDO1 by endMSCs was used as a primary biomarker for the immunomodulatory potential (55). Results obtained by ELISA firstly demonstrated an increase in IDO1 release when endMSCs were primed with 100 ng/ml of IFN γ . The significant increase was also observed when 100 ng/ml of IFN γ were combined with LPS and/or Poly (I:C) at 1 ng/ml. In the case of IFN γ at low concentrations (1 ng/ml), alone or in combination, the release of IDO1 was not increased when compared to control conditions.

Interestingly, the combination of 100 ng/ml IFN γ and 100 ng/ml TNF α achieved the highest level of IDO1 release (Figure 2). These results demonstrated a synergistic effect of IFN γ and TNF α on the immunomodulatory potential of endMSCs. Hence, endMSCs under these *in vitro* culture conditions were characterized in terms of surface marker expression, and their secretomes were concentrated and characterized.

Phenotypic profile of surface markers on endMSCs

endMSCs (n = 3) and endMSCs* (n = 3) phenotype was analyzed by flow cytometry using a large panel (n = 40) of monoclonal antibodies toward various cell surface markers (Supplementary Table 1). Our phenotypic analysis revealed a statistically significant difference in 9 out of 40 surface markers between endMSCs and endMSCs* (Figure 3A).

The following markers were significantly increased in endMSCs*: CD49e, CD54, CD56, CD58, CD63, CD126, CD152, and CD274. Uniquely, CD49d was significantly reduced in IFN γ /TNF α -primed cells (Figure 3B). Finally, differentially expressed antigens were classified according to Gene Ontology and Reactome Pathways. Our results revealed the classification of these markers in *Immune System Process* (GO:0002376) (CD54, CD49e, CD152, CD126, CD58, CD274, CD49d, CD63, CD56), *Cell Adhesion* (GO:007155) (CD54, CD49e, CD58, CD49d, CD63, CD56), *Cell Migration* (GO:0016477) (CD54, CD49e, CD126, CD58, CD49d, CD63), and *Response to Cytokine* (GO:0034097) (CD54, CD126, CD58, CD274, CD49d, CD56). The analysis by Reactome Biological Pathways demonstrated a classification in *Immune System* (HSA-168256) (CD54, CD152, CD126, CD58, CD274, CD49d, CD63, CD56), *Adaptive Immune System* (HSA-1280218) (CD54, CD152, CD274, CD49d), *Cytokine Signaling in Immune system* (HSA-1280215) (CD54, CD126, CD56), and *Integrin cell surface interactions* (HSA-216083) (CD54, CD49e, CD49d) (Figure 3C).

Effects of IFN γ /TNF α priming in S-endMSCs microRNAome

Particle size of secretomes was determined by nanoparticle tracking analysis. Particle diameter was 153.5 ± 63.05 nm, as already reported in one of our previous studies (39). A microRNAome NGS analysis was performed on concentrated S-endMSCs (n = 3) and S-endMSCs* (n = 3). A total of 628 miRNAs were identified from S-endMSCs. Supplementary Table 2 shows the expression in counts per millions (CPM) of top ten abundant miRNAs in the secretomes. Additionally, the comparison of the normalized and filtered expression values of CPM revealed that 40 of them (6.37%) were significantly different when S-endMSCs and S-endMSCs* were compared (*p* value adjusted by Benjamini-Hochberg FDR correction $\leq .05$). The top ten of miRNAs with the highest fold change

were hsa-miR-155-5p, hsa-miR-361-3p, hsa-miR-376a-3p, hsa-miR-424-3p, hsa-miR-27a-3p, hsa-miR-210-3p, hsa-miR-21-3p, hsa-miR-490-3p, hsa-miR-26a-2-3p, and hsa-miR-181a-5p (Supplementary Table 3).

Our results demonstrated that, 25 out of 40 significantly differentially expressed miRNAs (62.5%) were up-regulated in S-endMSCs*. These 25 miRNAs were selected for further analyses (unsupervised analysis and Gene Ontology enrichment analysis). To address the differences in miRNAome profile between the S-endMSCs* and S-endMSCs, unsupervised principal component analysis was used to study the potential clusters of these S-endMSCs based on the detected miRNAs. The result of the PCA indicated that each condition exhibited a unique miRNA profile, allowing a separation into well differentiated clusters (Figure 4A). The heat map-based unsupervised hierarchical clustering analysis showed the differences in these 25 miRNAs (Figure 4B) and corroborated the PCA analysis.

Gene Ontology enrichment analysis was performed to classify these up-regulated miRNAs. For this analysis, miRNet and TAM 2.0 software were used. Several biological processes turned out to be enriched, being the most relevant the terms: *Inflammatory Response* (GO:0006954) (64%), *Immune Response* (GO:0006955) (48%), *Cell Death* (GO:0008219) (48%), *Cell Aging* (GO:0007569) (44%), *Cell Cycle* (GO:0007049) (36%), *Innate Immune Response* (GO:0045087) (32%), *Cell Proliferation* (GO:0008283) (28%), *Cell Differentiation* (GO:0030154) (24%), *Angiogenesis* (GO:0001525) (24%), and *T-helper 17 Cell Differentiation* (GO:0072539) (20%).

miRNA Target Prediction in Inflammatory Response

According to microRNAome results, the up-regulated miRNAs were subsequently analyzed for determining the miRNA target genes using human miRTargetLink. Only miRNA-target interactions with strong experimental evidence were included. Our results demonstrated that, 105 genes were identified as miRNA targets (a total of 6 miRNAs were excluded because of a lack of connections). An enrichment analysis, carried out with FunRich, revealed that 22 genes out of 105 were included into Gene Ontology category of *Inflammation Response* (GO:0006954). These genes were sub-classified in four categories: *Innate Immune Response* (GO:0045087), *Adaptive Immune Response* (GO:0002250), *Positive Regulation of Inflammatory Response* (GO:0050728), and *Negative Regulation of Inflammatory Response* (GO:0050729). Some genes belonged to more than one category. The classification showed that 8 target genes were categorized in *Innate Immune Response* (*CD44*, *IFNG*, *PIK3CG*, *CSF1R*, *ICAM1*, *XIAP*, *APOE*, *NFKB1*), 6 target genes were categorized in *Positive Regulation of Inflammatory Response* (*PTGS2*, *IFNG*, *PIK3CG*, *ETS1*, *CEBPB*, *EGFR*), 5 target genes were categorized in *Negative Regulation of Inflammatory Response* (*IGF1*, *ETS1*, *APOE*, *KLF4*, *NFKB1*), and 4 target genes were categorized in *Adaptive Immune Response* (*BCL6*, *IFNG*, *PIK3CG*, *ICAM1*). Moreover, the genes: *ATM*, *KIT*, *FOS*, *SELE*, *SMAD1*, *NOTCH1*, and *HIF1A* were not included in these sub-categories. Finally, a Protein-miRNA Interaction Networks with 35 nodes and 51 edges were built using Cytoscape software (Figure 5).

Immunomodulatory assay of secretomes against *in vitro* stimulated lymphocytes

In order to evaluate the immunomodulatory effect of extracellular vesicles against *in vitro* stimulated lymphocytes, PBLs from a healthy donor were stimulated with anti-CD2, anti-CD3, and anti-CD28

beads. This stimulation partially mimics antigen-mediated activation and trigger the differentiation of CD4⁺ and CD8⁺ T cells towards effector-memory T cells (CD45RA⁻/CD62L⁻).

Lymphocyte activation assays were performed co-culturing PBLs in the presence of secretomes at 20, 40, and 80 µg/ml for 3 and 6 days. The most relevant results were obtained at day 6 with a secretome concentration of 40 µg/ml. The phenotype of *in vitro* stimulated T cells after co-culture with secretome 40 µg/ml at 6 days is shown in Figure 6. As expected, S-endMSCs* triggered a significant decrease in the percentage of CD4⁺ effector memory T-cells when compared to *in vitro* stimulated PBLs devoid of secretomes ($p = .0428$) and to S-endMSCs ($p = .0313$) (Figure 6A and 6C). Additionally, S-endMSCs* produced a significant decrease in the percentage of CD8⁺ effector memory T-cells when compared to *in vitro* stimulated PBLs ($p = .0043$) and to S-endMSCs ($p = .0283$) (Figure 6B and 6D). The percentage of effector-memory T cells was determined as the percentage of CD45RA⁻/CD62L⁻ cells on FSC/SSC-gated cells.

Discussion

Secretome derived from MSCs have become a promising tool for the regulation of adverse inflammatory events and to support regenerative processes. Among secretome sources, endometrial MSCs derived from menstrual blood (endMSCs) present many advantages: they can be obtained by non-invasive procedures, from multiple donors and without ethical concerns. Isolating and expanding these cells is easy and feasible, guaranteeing high growth rates in relatively short time (56). In earlier studies, we have demonstrated that their secreted vesicles had an immunomodulatory effect on CD4⁺ T cells (38). In addition, proteomic/genomic analyses revealed the presence of proteins and miRNAs involved in immunomodulatory pathways (39).

Here we aimed to improve *in vitro* culture conditions to enhance the immunomodulatory capacity of secretomes from endMSCs, and hence, their therapeutic effectiveness. According to bibliography, different priming -or licensing- strategies to enhance the immunomodulatory capacity of MSCs have been proposed (57). Pro-inflammatory cytokines, hypoxia, biological or chemical agents have been successfully used to enhance the immunomodulatory capacity against immune cells such as T cells, B cells, NK cells, neutrophils or dendritic cells (18,19). It should be pointed out that most of these results were obtained under *in vitro* conditions and several concerns about using these licensed cells in clinical settings have arisen. As an example, they may allow tumor development of pre-existing malignant cells (58).

Based on this idea, our first sets of experiments were focused on the optimization of priming conditions. IFN γ , TNF α , Poly (I:C), and LPS (separately or in combination) were used. For these experiments, IDO1 secretion was considered an “immunomodulatory biomarker” and allowed us to compare the efficiency of different priming conditions. It is important to note that, this enzyme has been also considered by other authors as a “potency marker” for MSC-mediated immune suppression (59). Our experimental conditions revealed that IFN γ itself enhanced the release of IDO1, which is in agreement with *in vitro* studies using adipose-derived MSCs (60). Additionally, it has been recently demonstrated that IFN γ causes chromatin remodeling at the IDO1 promoter increasing the mRNA levels (41). Our results were remarkable when IFN γ was combined with TNF α . These cytokines showed a synergistic effect and evidently increased the release of IDO1 from endMSCs. Although

the combination of these two cytokines is not new, and it has been already used to induce the immunomodulatory activity of MSCs (49,50), this the first report using MSCs from menstrual blood.

Using IDO1 as immunomodulatory biomarker, endMSC priming conditions were optimized. Hence, the next set of experiments was conducted to characterize the phenotype of IFN γ /TNF α -primed cells. In this analysis, a large panel of surface markers (n = 40) was analyzed to compare endMSCs* and endMSCs. As expected, endMSCs were positive for CD44, CD73, CD90, and CD105 with low levels of MHC class I molecule and negative expression of MHC class II. The statistics and paired comparisons revealed that 9 out of 40 surface markers were significantly increased in endMSCs*. Most of these markers were classified by Gene Ontology and Reactome in the categories *Immune System Process* (GO:0002376) and *Immune system* (R-HSA-168256) respectively.

It is important to discuss the significant differences observed in some of these molecules. NCAM-1 (CD56) is an adhesion molecule expressed in bone marrow-derived MSCs and associated with their migration and homing capacity (61). The surface molecule ICAM-1 (CD54) in MSCs promotes MSC homing to the focus of inflammation and immune organs (62) and its increased expression has been correlated with an immunomodulatory effect on dendritic cells (63). The expression of LFA3 (CD58) has been also described in bone marrow-derived MSCs and interacts with their ligands on T cells (64). Considering that preclinical and clinical studies have demonstrated that the homing/migration of systemically administered MSCs is very low (66), the increased expression of adhesion molecules ICAM-1, CD58, and NCAM-1 in IFN γ /TNF α -primed cells may improve homing and migration capacity to a target tissue.

Apart from adhesion molecules, our phenotypic analysis was also focused on immune checkpoint receptors such as CTLA4 (CD152) and PD-L1 (CD274). Here we demonstrate a significant increase of the inhibitory molecule CTLA4 (CD152) under IFN γ /TNF α priming. The expression of this protein has been previously described in the membrane of bone marrow-derived MSCs and its soluble form is released under hypoxic conditions (67). In our study, we also found a significant increase of CTLA4 in endMSCs*, which may have an immunomodulatory role by blocking CD28 co-stimulation on T cells. Similarly to CTLA4, we found that PD-L1 (CD274) was also increased after IFN γ /TNF α priming. This result is coincident with previous studies where bone marrow-derived MSCs express and secrete PD-L1 (CD274), that can be inducible under IFN γ and TNF α (68). The surface expression and inflammatory-mediated induction of CTLA4 and PD-L1 suggests that these molecules could be involved in the modulation of T cells and peripheral tolerance.

Finally, IL6R (CD126) emerged from our phenotypic analysis. endMSCs as adipose-derived MSCs (69) did not express -or had a very low expression of- CD126. Previous studies have demonstrated that CD126 cannot be induced in adipose-derived MSCs (using IFN γ or TGF β) (69). In contrast, in our experimental conditions we found a significant increase of CD126. The expression of IL6/IL6R has been correlated with the osteogenic (70) and adipogenic (71) differentiation of bone marrow-derived MSCs. Here we assume that the increase of CD126 may also reflect an increased susceptibility of endMSCs to IL6-mediated inflammation.

The second aim of this study was to analyze the secretomes from endMSCs*. As previously discussed, our group recently demonstrated the involvement of miRNAs in immunomodulatory pathways (39). Therefore, we hypothesized that IFN γ /TNF α may trigger the release of miRNAs that

target genes from inflammation and innate/adaptive immune responses. The analysis by NGS allowed us to identify a set of significantly increased ($n = 25$) and significantly decreased ($n = 16$) miRNAs following IFN γ /TNF α -priming. According to our previous studies, three of them were also significantly expressed when using IFN γ alone for priming endMSCs: hsa-miR-146b-5p, hsa-miR-376c-3p, and hsa-miR-490-3p (39). Similarly, here we confirm our previous findings which demonstrated that hsa-miR-143-3p, hsa-miR-199a-3p, hsa-let-7b-5p, hsa-miR-21-5p, hsa-miR-16-5p, hsa-let-7a-5p, and hsa-let-7f-5p, are the most abundant miRNAs in secretomes (39).

It is interesting to note that the PCA of NGS results evidenced the significant differences among secretomes under standard culture conditions and secretomes from endMSCs*. These results highlight the importance of cell culture conditions in the secretome release, and how inflammatory priming conditions determine the miRNAs content. Although some of these miRNAs may deserve a long discussion, we have focused our interest on those miRNAs which are significantly increased and target inflammatory-related genes.

The miRTargetLink analysis (72,73) allowed us to identify multiple query nodes on significantly increased miRNAs. The increase of hsa-miR-155-5p (log fold change = 5.05 and $p = .00009$) is especially relevant, since it targets genes involved in *Innate/Adaptive Immune Response*, such as *CSF1R*, *ICAM1* or *BCL6*. This result agrees with a recent study from E. Ragni et al., who demonstrated that miR-155-5p is overexpressed in extracellular vesicles from IFN- γ -primed adipose-derived MSCs (74). Similarly, an enhancement of miR-155-5p was previously reported in bone marrow-derived MSCs under IFN γ /TNF α stimulation, with the authors suggesting that this miRNA could inhibit the immunosuppressive capacity of MSCs by reducing the iNOS production (75). In contrast, a recent *in vitro* study using inhibitors of miR-155-5p in bone marrow-derived MSCs from rats demonstrated that miR-155-5p enhanced the differentiation of T cells towards Th2 and Treg cells (76). Based on our *in vitro* assays using *in vitro* stimulated T cells co-cultured with secretomes, we believe that miR-155-5p could be involved in the inhibition of T cell activation. Obviously, future studies must be conducted to validate this hypothesis.

The increase of hsa-miR-27a-3p was also significant in S-endMSCs* (log fold change = 4.35 and $p = .000005$). This miRNA has been recently described in extracellular vesicles derived from MSCs, and more importantly, it has been found to be transferred from vesicles to macrophages promoting M2 macrophage polarization (77). Furthermore, according to miRTargetLink, the gene *IFNG* is a target of hsa-miR-27a-3p, and this miRNA has been found to be involved in the regulation of *IRAK4*, a promoter of *NF- κ B* (78), which regulate inflammatory and immune genes.

In the case of hsa-miR-21-3p and hsa-miR-490-3p, these miRNAs were abundantly expressed and significantly increased in S-endMSCs under IFN γ priming (39). Similarly, hsa-miR-424-3p has been found to be increased in IFN γ -primed umbilical cord-derived MSCs (79). Regarding hsa-miR-185-5p, a recent study using EVs from MSCs have demonstrated that the enrichment of these vesicles with this miRNA alleviate the inflammatory response and reduce cell proliferation (80).

Altogether, data analysis by NGS revealed a myriad of miRNAs which are increased and decreased in S-endMSCs*. According to Gene Ontology, the targets for these miRNAs were found to be involved in the *regulation of inflammatory response*, so it is expected that the transference of these miRNAs to target cells may have an impact in the behavior of immune cells, and hence, in the

TH1/TH2 balance. Our functional studies using *in vitro* stimulated lymphocytes (that partially mimic an antigen-specific activation of T cells) could demonstrate their immunomodulatory capacity, however, further studies need to be performed to identify targeted genes in different immune cells. In a very recent study (81) equine amniotic MSCs were primed with a combination of IFN γ and TNF α demonstrating no additional immunosuppressive activity in an inflammatory *in vitro* model, compared to non-primed cells. Even though this study was performed with lower concentrations of IFN γ and TNF α on a different type of MSCs, it remarks that further research is necessary to confirm our insights.

In conclusion, our results have demonstrated that IFN γ and TNF α had a synergistic effect on IDO1 secretion, being a strong and efficient endMSCs priming strategy. Under this priming condition, surface molecules can be modified showing an increase of adhesion molecules, cytokine receptors and immune checkpoint receptors that may alter their biodistribution as well as their immunomodulatory activity. Here we hypothesize that IFN γ /TNF α may enhance the anti-inflammatory capacity of MSCs, as well as the migration/adhesion to inflammatory tissue. Finally, according to NGS and *in vitro* assays, IFN γ /TNF α -priming of endMSCs produce secretomes with a potent therapeutic/immunomodulatory potential.

Conflict of Interest

The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data Availability Statement

The datasets generated for this study can be found in Sequence Read Archive (SRA) data with the accession number PRJNA664968⁹.

Author Contributions

MÁP and JGC conceived and designed the experiments. MÁP, VÁ, EL, FM, MP, and JGC performed the experiments and analyzed the data. MÁP and JGC wrote the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by competitive grants, such as: “PFIS” contract (FI19/00041) from the National Institute of Health Carlos III (ISCIII, 2019 Call Strategic Action in Health 2019) to MÁP;

⁹ <http://www.ncbi.nlm.nih.gov/bioproject/664968>

MAFRESA S.L. (Grupo Jorge) grant (promoted by Jesús Usón Gargallo) to FM; “Sara Borrell” grant (CD19/00048) from ISCIII to EL; grant “TE-0001-19” from Consejería de Educación y Empleo (co-funded by European Social Fund -ESF- “Investing in your future”, ayuda para el fomento de la contratación de personal de apoyo a la investigación en la Comunidad Autónoma de Extremadura to MP. Costs for experimental development were funded by grant “CB16/11/00494” from CIBER-CV and Ayuda Grupos catalogados de la Junta de Extremadura (GR18199) from Junta de Extremadura , Consejería de Economía, Ciencia y Agenda Digital (co-funded by European Regional Development Fund – ERDF) to FS-M; JGC received fundings from the ISCIII through a “Miguel Servet I” grant (MS17/00021) co-funded by ERDF/ESF “A way to make Europe”/“Investing in your future”, funding from the projects “CP17/00021” and “PI18/0911” (co-funded by ERDF/ESF), and by Junta de Extremadura through a “IB16168” grant (co-funded by ERDF/ESF). The funders had no role in study designs, data collection and analysis, decision to publish, or preparation of the manuscript.

List of abbreviations

BSA, Bovine Serum Albumin; CPM, Counts Per Million; DMEM, Dulbecco's Modified Eagle's medium; EDGE, Empirical analysis of Differential Gene Expression; ELISA, Enzyme-Linked ImmunoSorbent Assay; endMSCs, Endometrial-derived stromal/Mesenchymal Stem Cells; endMSCs*, IFN γ /TNF α -primed Endometrial-derived stromal/Mesenchymal Stem Cells; endMSCs, Endometrial-derived stromal/Mesenchymal Stem Cells; EVendMSCs, Extracellular Vesicles from Endometrial-derived Mesenchymal Stromal/Stem Cells; EVs, Extracellular Vesicles; FBS, Fetal Bovine Serum; FDR, False Discovery Rate; GO, Gene Ontology; IDO1, Indoleamine 2,3-dioxygenase; IFN γ , Interferon gamma; LPS, Lipopolysaccharide; MFI, Mean Fluorescence Intensity; FMO; Fluorescence Minus One; MSCs, Mesenchymal Stromal Cells; NGS, Next Generation Sequencing; PBLs, Peripheral blood lymphocytes; PBS, Phosphate buffered saline; PCA, Principal Component Analysis; Poly (I:C), Polyinosinic: polycytidylic acid; QPCR, Quantitative Real-Time Polymerase Chain Reaction; SD, Standard Deviation; SAR, Sequence Read Archive; S-endMSCs; Secretome from Endometrial-derived Mesenchymal Stromal/Stem Cells; S-endMSCs*; Secretome from IFN γ /TNF α -primed Endometrial-derived Mesenchymal Stromal/Stem Cells; SI, Stain Index; TLR, Toll-Like Receptor; TNF α , Tumor Necrosis Factor alpha; UMI, Unique Molecular Index.

Acknowledgments

Lymphocyte activation assays were performed by ICTS Nanbiosis (Unit 14 at CCMIJU). The authors acknowledge the contribution of Joaquín González for the technical support in figures handling.

Bibliography

1. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy*. 2005;7(5):393–5.

- 493 2. Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JAW. Mesenchymal stromal
494 cells derived from various tissues: Biological, clinical and cryopreservation aspects.
495 Cryobiology. 2015 Oct;71(2):181–97.
- 496 3. Bozorgmehr M, Gurung S, Darzi S, Nikoo S, Kazemnejad S, Zarnani A-H, et al. Endometrial
497 and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical
498 Application. Front Cell Dev Biol. 2020;8:497.
- 499 4. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Hum
500 Reprod Update. 2016 Mar;22(2):137–63.
- 501 5. Masuda H, Anwar SS, Bühring H-J, Rao JR, Gargett CE. A novel marker of human endometrial
502 mesenchymal stem-like cells. Cell Transplant. 2012;21(10):2201–14.
- 503 6. Schwab KE, Gargett CE. Co-expression of two perivascular cell markers isolates mesenchymal
504 stem-like cells from human endometrium. Hum Reprod. 2007 Nov;22(11):2903–11.
- 505 7. Kyurkchiev S, Shterev A, Dimitrov R. Assessment of presence and characteristics of
506 multipotent stromal cells in human endometrium and decidua. Reprod Biomed Online. 2010
507 Mar;20(3):305–13.
- 508 8. Wang H, Jin P, Sabatino M, Ren J, Civini S, Bogin V, et al. Comparison of endometrial
509 regenerative cells and bone marrow stromal cells. J Transl Med. 2012 Oct 5;10:207.
- 510 9. Schüring AN, Schulte N, Kelsch R, Röpke A, Kiesel L, Götte M. Characterization of
511 endometrial mesenchymal stem-like cells obtained by endometrial biopsy during routine
512 diagnostics. Fertil Steril. 2011 Jan;95(1):423–6.
- 513 10. Lucas ES, Dyer NP, Fishwick K, Ott S, Brosens JJ. Success after failure: the role of endometrial
514 stem cells in recurrent miscarriage. Reprod Camb Engl. 2016 Nov;152(5):R159-166.
- 515 11. Dominici M, Blanc KL, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal
516 criteria for defining multipotent mesenchymal stromal cells. The International Society for
517 Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.
- 518 12. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune
519 system. Nat Rev Immunol. 2012 Apr 25;12(5):383–96.
- 520 13. Levy O, Kuai R, Siren EMJ, Bhare D, Milton Y, Nissar N, et al. Shattering barriers toward
521 clinically meaningful MSC therapies. Sci Adv. 2020 Jul;6(30):eaba6884.
- 522 14. Nikoo S, Ebtekar M, Jeddi-Tehrani M, Shervin A, Bozorgmehr M, Kazemnejad S, et al. Effect
523 of menstrual blood-derived stromal stem cells on proliferative capacity of peripheral blood
524 mononuclear cells in allogeneic mixed lymphocyte reaction. J Obstet Gynaecol Res. 2012
525 May;38(5):804–9.

- 526 15. Nikoo S, Ebtekar M, Jeddi-Tehrani M, Shervin A, Bozorgmehr M, Vafaei S, et al. Menstrual
527 blood-derived stromal stem cells from women with and without endometriosis reveal different
528 phenotypic and functional characteristics. *Mol Hum Reprod*. 2014 Jan 9;20(9):905–18.
- 529 16. Peron JPS, Jazedje T, Brandão WN, Perin PM, Maluf M, Evangelista LP, et al. Human
530 endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous
531 system of EAE mice. *Stem Cell Rev*. 2012 Sep;8(3):940–52.
- 532 17. Du X, Yuan Q, Qu Y, Zhou Y, Bei J. Endometrial Mesenchymal Stem Cells Isolated from
533 Menstrual Blood by Adherence. *Stem Cells Int*. 2016;2016:3573846.
- 534 18. Baldari S, Di Rocco G, Piccoli M, Pozzobon M, Muraca M, Toietta G. Challenges and
535 Strategies for Improving the Regenerative Effects of Mesenchymal Stromal Cell-Based
536 Therapies. *Int J Mol Sci*. 2017 Oct 2;18(10).
- 537 19. Noronha NC N de C, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, Covas DT, et
538 al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.
539 *Stem Cell Res Ther* [Internet]. 2019 May 2 [cited 2020 Apr 2];10. Available from:
540 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498654/>
- 541 20. Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller EK, et al.
542 Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis
543 Which Is Partly Rescued by IFN γ Licensing. *Stem Cells Dayt Ohio*. 2016;34(9):2429–42.
- 544 21. Croes M, Oner FC, Kruyt MC, Blokhuis TJ, Bastian O, Dhert WJA, et al. Proinflammatory
545 Mediators Enhance the Osteogenesis of Human Mesenchymal Stem Cells after Lineage
546 Commitment. *PloS One*. 2015;10(7):e0132781.
- 547 22. Carrero R, Cerrada I, Lledó E, Dopazo J, García-García F, Rubio M-P, et al. IL1 β induces
548 mesenchymal stem cells migration and leucocyte chemotaxis through NF- κ B. *Stem Cell Rev*
549 *Rep*. 2012 Sep;8(3):905–16.
- 550 23. Gorin C, Rochefort GY, Bascetin R, Ying H, Lesieur J, Sadoine J, et al. Priming Dental Pulp
551 Stem Cells With Fibroblast Growth Factor-2 Increases Angiogenesis of Implanted Tissue-
552 Engineered Constructs Through Hepatocyte Growth Factor and Vascular Endothelial Growth
553 Factor Secretion. *Stem Cells Transl Med*. 2016 Mar;5(3):392–404.
- 554 24. Sivanathan KN, Rojas-Canales DM, Hope CM, Krishnan R, Carroll RP, Gronthos S, et al.
555 Interleukin-17A-Induced Human Mesenchymal Stem Cells Are Superior Modulators of
556 Immunological Function. *Stem Cells*. 2015 Sep;33(9):2850–63.
- 557 25. Oliveira-Bravo M, Sangiorgi BB, Schiavinato JLDS, Carvalho JL, Covas DT, Panepucci RA, et
558 al. LL-37 boosts immunosuppressive function of placenta-derived mesenchymal stromal cells.
559 *Stem Cell Res Ther*. 2016 30;7(1):189.

- 560 26. Liu J, Zhu P, Song P, Xiong W, Chen H, Peng W, et al. Pretreatment of Adipose Derived Stem
561 Cells with Curcumin Facilitates Myocardial Recovery via Antiapoptosis and Angiogenesis.
562 *Stem Cells Int.* 2015;2015:638153.
- 563 27. Kim YS, Kwon JS, Hong MH, Kang WS, Jeong H, Kang H, et al. Restoration of angiogenic
564 capacity of diabetes-insulted mesenchymal stem cells by oxytocin. *BMC Cell Biol.* 2013 Sep
565 11;14:38.
- 566 28. Shuai Y, Liao L, Su X, Yu Y, Shao B, Jing H, et al. Melatonin Treatment Improves
567 Mesenchymal Stem Cells Therapy by Preserving Stemness during Long-term In Vitro
568 Expansion. *Theranostics.* 2016;6(11):1899–917.
- 569 29. Xu R, Chen W, Zhang Z, Qiu Y, Wang Y, Zhang B, et al. Integrated data analysis identifies
570 potential inducers and pathways during the endothelial differentiation of bone-marrow stromal
571 cells by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine. *Gene.* 2018 May 30;657:9–
572 18.
- 573 30. Linares GR, Chiu C-T, Scheuing L, Leng Y, Liao H-M, Maric D, et al. Preconditioning
574 mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances
575 therapeutic efficacy in a mouse model of Huntington's disease. *Exp Neurol.* 2016;281:81–92.
- 576 31. Lim J, Lee S, Ju H, Kim Y, Heo J, Lee H-Y, et al. Valproic acid enforces the priming effect of
577 sphingosine-1 phosphate on human mesenchymal stem cells. *Int J Mol Med.* 2017
578 Sep;40(3):739–47.
- 579 32. Zhilai Z, Biling M, Sujun Q, Chao D, Benchao S, Shuai H, et al. Preconditioning in lowered
580 oxygen enhances the therapeutic potential of human umbilical mesenchymal stem cells in a rat
581 model of spinal cord injury. *Brain Res.* 2016 01;1642:426–35.
- 582 33. Beegle J, Lakatos K, Kalomoiris S, Stewart H, Isseroff RR, Nolta JA, et al. Hypoxic
583 preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival,
584 and promotes cell retention in vivo. *Stem Cells Dayt Ohio.* 2015 Jun;33(6):1818–28.
- 585 34. Lee JH, Yoon YM, Lee SH. Hypoxic Preconditioning Promotes the Bioactivities of
586 Mesenchymal Stem Cells via the HIF-1 α -GRP78-Akt Axis. *Int J Mol Sci.* 2017 Jun 21;18(6).
- 587 35. Lan Y-W, Choo K-B, Chen C-M, Hung T-H, Chen Y-B, Hsieh C-H, et al. Hypoxia-
588 preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. *Stem*
589 *Cell Res Ther.* 2015 May 20;6:97.
- 590 36. Showalter MR, Wancewicz B, Fiehn O, Archard JA, Clayton S, Wagner J, et al. Primed
591 mesenchymal stem cells package exosomes with metabolites associated with
592 immunomodulation. *Biochem Biophys Res Commun.* 2019 May 14;512(4):729–35.
- 593 37. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell
594 (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2
595 phenotype. *PloS One.* 2010 Apr 26;5(4):e10088.

38. Álvarez V, Sánchez-Margallo FM, Macías-García B, Gómez-Serrano M, Jorge I, Vázquez J, et al. The immunomodulatory activity of extracellular vesicles derived from endometrial mesenchymal stem cells on CD4+ T cells is partially mediated by TGFβ. *J Tissue Eng Regen Med*. 2018 Oct;12(10):2088–98.
39. Marinaro F, Gómez-Serrano M, Jorge I, Silla-Castro JC, Vázquez J, Sánchez-Margallo FM, et al. Unraveling the Molecular Signature of Extracellular Vesicles From Endometrial-Derived Mesenchymal Stem Cells: Potential Modulatory Effects and Therapeutic Applications. *Front Bioeng Biotechnol*. 2019;7:431.
40. François M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. *Mol Ther J Am Soc Gene Ther*. 2012 Jan;20(1):187–95.
41. Rovira Gonzalez YI, Lynch PJ, Thompson EE, Stultz BG, Hursh DA. In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter. *Cytotherapy*. 2016;18(9):1114–28.
42. Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. *Stem Cells Dev*. 2010 Nov;19(11):1803–9.
43. Varkouhi AK, Jerkic M, Ormesher L, Gagnon S, Goyal S, Rabani R, et al. Extracellular Vesicles from Interferon-γ-primed Human Umbilical Cord Mesenchymal Stromal Cells Reduce Escherichia coli-induced Acute Lung Injury in Rats. *Anesthesiology*. 2019;130(5):778–90.
44. Gonçalves F da C, Luk F, Korevaar SS, Bouzid R, Paz AH, López-Iglesias C, et al. Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes. *Sci Rep*. 2017 21;7(1):12100.
45. Liang Y-C, Wu Y-P, Li X-D, Chen S-H, Ye X-J, Xue X-Y, et al. TNF-α-induced exosomal miR-146a mediates mesenchymal stem cell-dependent suppression of urethral stricture. *J Cell Physiol*. 2019 Dec;234(12):23243–55.
46. Lu Z, Chen Y, Dunstan C, Roohani-Esfahani S, Zreiqat H. Priming Adipose Stem Cells with Tumor Necrosis Factor-Alpha Preconditioning Potentiates Their Exosome Efficacy for Bone Regeneration. *Tissue Eng Part A*. 2017;23(21–22):1212–20.
47. Mead B, Chamling X, Zack DJ, Ahmed Z, Tomarev S. TNFα-Mediated Priming of Mesenchymal Stem Cells Enhances Their Neuroprotective Effect on Retinal Ganglion Cells. *Invest Ophthalmol Vis Sci*. 2020 Feb 7;61(2):6–6.
48. Harting MT, Srivastava AK, Zhaorigetu S, Bair H, Prabhakara KS, Toledano Furman NE, et al. Inflammation-Stimulated Mesenchymal Stromal Cell-Derived Extracellular Vesicles Attenuate Inflammation. *Stem Cells Dayt Ohio*. 2018;36(1):79–90.

- 630 49. Domenis R, Cifù A, Quaglia S, Pistis C, Moretti M, Vicario A, et al. Pro inflammatory stimuli
631 enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived
632 exosomes. *Sci Rep.* 2018 06;8(1):13325.
- 633 50. An J-H, Li Q, Bhang D-H, Song W-J, Youn H-Y. TNF- α and INF- γ primed canine stem cell-
634 derived extracellular vesicles alleviate experimental murine colitis. *Sci Rep.* 2020 Feb
635 7;10(1):2115.
- 636 51. Marinaro F, Macías-García B, Sánchez-Margallo FM, Blázquez R, Álvarez V, Matilla E, et al.
637 Extracellular vesicles derived from endometrial human mesenchymal stem cells enhance
638 embryo yield and quality in an aged murine model. *Biol Reprod.* 2019 May 1;100(5):1180–92.
- 639 52. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A Software
640 Environment for Integrated Models of Biomolecular Interaction Networks. *Genome Res.* 2003
641 Nov;13(11):2498.
- 642 53. Pathan M, Keerthikumar S, Chisanga D, Alessandro R, Ang C-S, Askenase P, et al. A novel
643 community driven software for functional enrichment analysis of extracellular vesicles data. *J*
644 *Extracell Vesicles.* 2017;6(1):1321455.
- 645 54. Pathan M, Keerthikumar S, Ang C-S, Gangoda L, Quek CYJ, Williamson NA, et al. FunRich:
646 An open access standalone functional enrichment and interaction network analysis tool.
647 *PROTEOMICS.* 2015;15(15):2597–601.
- 648 55. Bernardo ME, Fibbe WE. Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation.
649 *Cell Stem Cell.* 2013 Oct 3;13(4):392–402.
- 650 56. Toyoda M, Cui C, Umezawa A. Myogenic transdifferentiation of menstrual blood-derived cells.
651 *Acta Myol.* 2007 Dec;26(3):176–8.
- 652 57. Guerrouahen BS, Sidahmed H, Al Sulaiti A, Al Khulaifi M, Cugno C. Enhancing Mesenchymal
653 Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System.
654 *Stem Cells Int [Internet].* 2019 Aug 5 [cited 2020 Jun 29];2019. Available from:
655 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701346/>
- 656 58. Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, et al. Risk of
657 tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations
658 and regulatory viewpoints. *Cytotherapy.* 2013 Jul;15(7):753–9.
- 659 59. Guan Q, Li Y, Shpiruk T, Bhagwat S, Wall DA. Inducible indoleamine 2,3-dioxygenase 1 and
660 programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells.
661 *Cytotherapy.* 2018;20(5):639–49.
- 662 60. DelaRosa O, Lombardo E, Beraza A, Mancheño-Corvo P, Ramirez C, Menta R, et al.
663 Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the
664 modulation of lymphocyte proliferation by human adipose-derived stem cells. *Tissue Eng Part*
665 *A.* 2009;15(10):2795–806.

61. Shi Y, Xia Y-Y, Wang L, Liu R, Khoo K-S, Feng Z-W. Neural cell adhesion molecule modulates mesenchymal stromal cell migration via activation of MAPK/ERK signaling. *Exp Cell Res*. 2012 Oct 15;318(17):2257–67.
62. Li X, Wang Q, Ding L, Wang Y-X, Zhao Z-D, Mao N, et al. Intercellular adhesion molecule-1 enhances the therapeutic effects of MSCs in a dextran sulfate sodium-induced colitis models by promoting MSCs homing to murine colons and spleens. *Stem Cell Res Ther*. 2019 23;10(1):267.
63. Tang B, Li X, Liu Y, Chen X, Li X, Chu Y, et al. The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease. *Cell Physiol Biochem*. 2018;46(6):2624–35.
64. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identification of IL-10 and TGF- β Transcripts Involved in the Inhibition of T-Lymphocyte Proliferation During Cell Contact With Human Mesenchymal Stem Cells. *Gene Expr*. 2018 Jul 5;13(4–5):217–26.
65. Ridger VC, Wagner BE, Wallace WA, Hellewell PG. Differential effects of CD18, CD29, and CD49 integrin subunit inhibition on neutrophil migration in pulmonary inflammation. *J Immunol Baltim Md 1950*. 2001 Mar 1;166(5):3484–90.
66. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. *Blood*. 2003 Apr 15;101(8):2999–3001.
67. Gaber T, Schönbeck K, Hoff H, Tran CL, Strehl C, Lang A, et al. CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells. *Int J Mol Sci [Internet]*. 2018 Aug 7 [cited 2020 Jul 1];19(8). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121442/>
68. Davies LC, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. *Stem Cells Dayt Ohio*. 2017;35(3):766–76.
69. Wu Y, Hoogduijn MJ, Baan CC, Korevaar SS, de Kuiper R, Yan L, et al. Adipose Tissue-Derived Mesenchymal Stem Cells Have a Heterogenic Cytokine Secretion Profile. *Stem Cells Int*. 2017;2017:4960831.
70. Xie Z, Tang S, Ye G, Wang P, Li J, Liu W, et al. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells. *Stem Cell Res Ther [Internet]*. 2018 Jan 22 [cited 2020 Jul 3];9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776773/>
71. Deng W, Chen H, Su H, Wu X, Xie Z, Wu Y, et al. IL6 Receptor Facilitates Adipogenesis Differentiation of Human Mesenchymal Stem Cells through Activating P38 Pathway. *Int J Stem Cells*. 2020 Mar 30;13(1):142–50.

72. Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. *Nucleic Acids Res.* 2015 Jan;43(Database issue):D146-152.
73. Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. *Genome Biol.* 2019 22;20(1):18.
74. Ragni E, Perucca Orfei C, De Luca P, Mondadori C, Viganò M, Colombini A, et al. Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease. *Stem Cell Res Ther.* 2020 Apr 28;11(1):165.
75. Xu C, Ren G, Cao G, Chen Q, Shou P, Zheng C, et al. miR-155 Regulates Immune Modulatory Properties of Mesenchymal Stem Cells by Targeting TAK1-binding Protein 2. *J Biol Chem.* 2013 Apr 19;288(16):11074–9.
76. Zhang X, Hua F, Yang Z, Chen Y, Teng X, Huang H, et al. Enhancement of Immunoregulatory Function of Modified Bone Marrow Mesenchymal Stem Cells by Targeting SOCS1 [Internet]. Vol. 2018, *BioMed Research International*. Hindawi; 2018 [cited 2020 Jul 10]. p. e3530647. Available from: <https://www.hindawi.com/journals/bmri/2018/3530647/>
77. Wang J, Huang R, Xu Q, Zheng G, Qiu G, Ge M, et al. Mesenchymal Stem Cell–Derived Extracellular Vesicles Alleviate Acute Lung Injury Via Transfer of miR-27a-3p*. *Crit Care Med.* 2020 Jul;48(7):e599.
78. Wang J, Jia Z, Wei B, Zhou Y, Niu C, Bai S, et al. MicroRNA-27a restrains the immune response to mycobacterium tuberculosis infection by targeting IRAK4, a promoter of the NF-κB pathway. :8.
79. Chi Y, Cui J, Wang Y, Du W, Chen F, Li Z, et al. Interferon-γ alters the microRNA profile of umbilical cord-derived mesenchymal stem cells. *Mol Med Rep.* 2016 Nov;14(5):4187–97.
80. Wang L, Yin P, Wang J, Wang Y, Sun Z, Zhou Y, et al. Delivery of mesenchymal stem cells-derived extracellular vesicles with enriched miR-185 inhibits progression of OPMD. *Artif Cells Nanomedicine Biotechnol.* 2019 Dec 4;47(1):2481–91.
81. Lange-Consiglio A, Romele P, Magatti M, Silini A, Idda A, Martino NA, et al. Priming with inflammatory cytokines is not a prerequisite to increase immune-suppressive effects and responsiveness of equine amniotic mesenchymal stromal cells. *Stem Cell Res Ther.* 2020 Mar 4;11(1):99.

1. Figure legends

Figure 1. Graphic overview of key experimental procedures. (A) IFN γ , TNF α , LPS, and Poly (I:C) were used at different concentrations, single or in combination, to prime *in vitro* cultured endMSCs. The optimal priming strategy was identified by ELISA in terms of IDO1 release. (B) In

accordance with ELISA results, endMSCs were primed with 100 ng/ml IFN γ /TNF α , and the phenotypic profile of primed and control endMSCs was determined by flow cytometry. EndMSC and endMSC* collected medium were concentrate to get secretomes. The molecular profile of secretomes was analyzed by Next Generation Sequencing (NGS). In addition, the immunomodulatory activity of control S-endMSCs or S-endMSCs* was analyzed in a lymphocyte activation assay. Images have been created with BioRender (<https://app.biorender.com/>).

Figure 2. Release of soluble IDO1 by primed endMSCs. endMSCs (n = 3) were primed with several combinations and concentrations of proinflammatory cytokines: IFN γ and TNF α , and TLR ligands: LPS and Poly (I:C). Levels of released IDO1 by the cells were tested by ELISA. A paired *t*-test was used to compare IDO1 levels in control endMSCs with the different priming conditions. Error bars represent the standard deviations of data. Asterisks indicate statistically significant differences: **p* < .05, ***p* < .01, *** *p* < .001.

Figure 3. Phenotypic surface marker expression on endMSCs. Analysis of surface markers in control endMSCs (n = 3) and endMSCs* (n = 3) using 100 ng/ml IFN γ and 100 ng/ml TNF α at 3 days. (A) The expression level of 40 cell surface markers (Stain Index (SI) value) were illustrated in a heat map. To compare control endMSCs and endMSCs*, a paired *t*-test was carried out and *p* < .05 were considered statistically significant. The color scale for the SI values gives the highest expression values (red) and the lowest (blue); the orange color scale indicates the grade of signification, being the most significant ones in dark orange. (B) Representative histograms of statistically different markers are shown. The expression in endMSCs is represented by a black lined histogram and in endMSCs* by a discontinuous line. The opaque gray histogram corresponds to the fluorescence negative control. (C) Reactome and Gene Ontology enrichment analyses of statistically significant different markers were performed by adjusting *p* value by Benjamini-Hochberg FDR correction < .01. Graph bars represent the number of surface markers included into each category of Reactome (orange) and Gene Ontology (blue).

Figure 4. Effects of IFN γ /TNF α priming on S-endMSCs microRNAome. A selection of the 25 miRNAs which showed a significant increase in S-endMSC*, were used for further analyses. (A) Principal Component Analysis (PCA) plots. Score plot for PC1 (57.1% variance explained) vs. PC2 (26.8% variance explained). (B) Hierarchical Clustering of secretomes (S-endMSC1, S-endMSC2, S-endMSC3) and the different conditions (basal red and primed in blue) together with the heat map corresponding to the selected miRNA expressions. (C) Enrichment analysis revealed a significant implication of the selected miRNAs in Gene Ontology categories (*p* value adjusted by Benjamini-Hochberg FDR correction < .01). Graph bars represent the number of miRNAs in each category.

Figure 5. Predicted target genes for miRNAs. Target genes of significantly increased miRNAs from S-endMSC*. Target genes classified into the category *Inflammatory Response category* (GO:0006954) were sub-classified into four sub-categories (*Innate Immune Response* (orange), *Adaptive Immune Response* (blue), *Positive Regulation of Inflammatory Response* (green), and *Negative Regulation of Inflammatory Response* (red). Interaction network of gene targets (dark blue ellipses) and miRNAs (brown rectangles) were illustrated using Cytoscape Software.

Figure 6. Lymphocyte activation assays for the evaluation of Secretomes. PBLs from a healthy donor were stimulated and simultaneously co-cultured with S-endMSCs (n = 3) and S-endMSCs* (n = 3) at 40 µg/ml for 6 days. (A) Percentage of CD4+ and (B) percentage of CD8+ effector memory T cells (CD45RA-/CD62L-). Data from non-stimulated PBLs is not shown. Values represent the mean ± SD of independently performed experiments. Data were statistically analyzed using a paired *t*-test and *p* value was considered significant at < .05. *Statistically significant differences (*p* < .05). **Statistically significant comparison (*p* < .005). A representative dot plot of each condition is illustrated: (C) CD4+ and (D) CD8+ T cells. The gates for CD45RA and CD62L were drawn according to negative controls.

Supplementary table 1. Panel of human monoclonal antibodies used for the phenotypic characterization of endMSCs and IFNγ/TNFα-primed endMSCs by flow cytometry. The table includes relevant information of these markers.

Supplementary table 2. The most abundant miRNAs in secretomes (S-endMSCs and S-endMSC*).

Supplementary table 3. The top ten of miRNAs with the highest fold change in secretome samples.

(A)**COMBINATIONS****1 ng/ml
LPS****1 ng/ml
Poly (I:C)****1 ng/ml
TNF α** **1 ng/ml
IFN γ** **100 ng/ml
TNF α** **100 ng/ml
IFN γ**

bioRxiv preprint doi: <https://doi.org/10.1101/2021.06.10.447490>; this version posted June 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Primed-
endMSCs**72 h** Soluble IDO1
ELISA**(B)**Control **72 h**

Flow Cytometry

Phenotypic Surface
Marker Expression **72 h** IFN γ / TNF α EVendMSC
Purification Immunomodulatory
Activity Assay miRNA Analysis
by NGSSelected
priming

(A)

Antigen	endMSCs			endMSCs*			p value
	endMSC1	endMSC2	endMSC3	endMSCs1	endMSCs2	endMSC3	
CD44	298.30	19.49	15.64	373.84	101.87	417.41	0.225
CD73	86.08	14.99	8.72	377.66	109.72	237.43	0.072
CD29	32.22	15.59	44.67	16.00	8.67	40.11	0.122
CD49e	45.78	2.88	2.77	113.34	76.92	65.59	0.002
CD9	9.97	5.09	23.07	4.58	2.42	4.42	0.213
CD59	14.27	15.73	1.32	4.84	9.96	25.41	0.806
CD49b	11.97	6.55	9.49	12.72	7.86	13.01	0.159
CD55	21.39	2.40	1.47	72.01	16.99	33.63	0.089
CD49c	10.21	5.29	8.50	9.54	3.65	7.30	0.054
CD49f	4.89	10.58	5.06	2.21	3.84	1.46	0.072
CD105	14.40	1.20	0.69	29.49	20.37	33.63	0.053
CD49a	10.28	2.02	1.69	58.31	20.25	71.87	0.094
CD166	1.19	3.74	8.83	3.39	10.77	0.45	0.957
CD90	11.52	0.23	0.88	28.46	5.28	19.21	0.086
CD61	5.75	1.20	5.40	2.77	1.09	14.34	0.641
CD51	5.86	0.82	5.42	22.54	5.17	18.74	0.090
CD107a	9.47	0.98	0.99	35.54	93.41	31.60	0.146
CD71	6.69	0.61	2.95	0.85	2.49	1.88	0.553
CD49d	2.75	3.57	2.26	0.90	1.21	1.19	0.042
CD58	7.22	0.43	0.52	25.15	13.45	20.93	0.016
HLAI	5.06	0.61	1.60	58.76	22.05	50.32	0.054
CD54	3.21	1.75	2.18	261.73	217.63	133.17	0.033
CD16	4.21	1.13	1.66	1.79	2.44	1.44	0.723
CD274	5.68	0.37	0.62	44.43	40.97	41.27	<0.001
CD273	5.89	0.15	0.22	10.96	5.50	12.09	0.079
CD38	3.19	0.14	2.00	5.21	37.24	5.67	0.338
CD66	3.73	0.10	0.32	10.34	2.52	14.55	0.154
CD279	1.03	1.90	0.66	1.25	0.28	2.17	0.972
CD282	3.26	0.18	0.10	5.06	11.56	6.03	0.149
CD152	2.86	0.21	0.11	7.52	4.24	3.63	0.007
CD56	2.21	0.44	0.18	3.40	2.70	1.67	0.035
CD120b	2.54	0.12	0.13	4.22	4.47	2.10	0.087
CD20	0.68	0.07	1.82	1.28	0.37	0.92	0.999
CD48	2.16	0.09	0.09	3.66	3.84	1.75	0.086
CD126	1.55	0.08	0.07	2.67	1.92	1.67	0.019
CD62E	1.35	0.10	0.12	9.32	2.87	2.42	0.139
CD50	0.75	0.12	0.06	4.28	1.58	1.52	0.089
CD133	0.73	0.14	0.03	8.18	0.83	3.11	0.199
CD63	0.09	0.26	0.05	18.12	14.21	18.71	0.008
HLAII	0.24	0.00	0.01	4.07	1.76	2.09	0.058

Cell Line

●endMSC01

■endMSC02

▲endMSC03

Treatment

●S-endMSCs

●S-endMSCs*

PC2 (26.8%)

PC1 (57.1%)

endMSC2

endMSC1

endMSC3

endMSC1

endMSC2

endMSC3

S-endMSCs

S-endMSCs*

hsa-miR-424-3p

hsa-miR-155-5p

hsa-miR-29c-3p

hsa-miR-7-5p

hsa-miR-27a-3p

hsa-miR-125a-5p

hsa-miR-34a-5p

hsa-miR-146b-5p

hsa-miR-199a-5p

hsa-miR-148b-3p

hsa-miR-490-3p

hsa-miR-185-5p

hsa-miR-210-3p

hsa-miR-221-3p

hsa-miR-376a-3p

hsa-miR-181a-5p

hsa-miR-181b-5p

hsa-miR-26a-2-3p

hsa-miR-30b-5p

hsa-miR-221-5p

hsa-miR-21-3p

hsa-miR-30a-3p

hsa-miR-361-3p

hsa-miR-376c-3p

hsa-miR-199a-3p

2

1.5

1

0.5

0

-0.5

-1

T-helper 17 Cell Differentiation (GO:0072539)

Angiogenesis (GO:0001525)

Cell Differentiation (GO:0030154)

Cell Proliferation (GO:0008283)

Cell Cycle (GO:0007049)

Cell Death (GO:0008219)

Cell Aging (GO:0007569)

Innate Immune Response (GO:0045087)

Immune Response (GO:0006955)

Inflammatory Response (GO:0006954)

0

2

4

6

8

10

12

14

16

hsa-mir-27a-3p, hsa-mir-181a-5p, hsa-mir-210-3p, hsa-mir-155-5p, hsa-mir-21-3p

hsa-mir-30a-3p, hsa-mir-34a-5p, hsa-mir-210-3p, hsa-mir-221-3p, hsa-mir-21-3p, hsa-mir-221-5p

hsa-mir-34a-5p, hsa-mir-210-3p, hsa-mir-125a-5p, hsa-mir-185-5p, hsa-mir-155-5p, hsa-mir-424-3p

hsa-mir-199a-5p, hsa-mir-199a-3p, hsa-mir-34a-5p, hsa-mir-221-3p, hsa-mir-29c-3p, hsa-mir-21-3p, hsa-mir-221-5p

hsa-mir-34a-5p, hsa-mir-210-3p, hsa-mir-221-3p, hsa-mir-221-5p, hsa-mir-185-5p, hsa-mir-21-3p, hsa-mir-424-3p, hsa-mir-155-5p, hsa-mir-27a-3p

hsa-mir-7-5p, hsa-mir-34a-5p, hsa-mir-181a-5p, hsa-mir-181b-5p, hsa-mir-221-3p, hsa-mir-221-5p, hsa-mir-30b-5p, hsa-mir-29c-3p, hsa-mir-21-3p, hsa-mir-155-5p, hsa-mir-210-3p, hsa-miR-376a-3p

hsa-mir-30a-3p, hsa-mir-7-5p, hsa-mir-34a-5p, hsa-mir-181a-5p, hsa-mir-181b-5p, hsa-mir-221-3p, hsa-mir-221-5p, hsa-mir-30b-5p, hsa-mir-155-5p, hsa-mir-146b-5p, hsa-mir-21-3p

hsa-mir-30a-3p, hsa-mir-181a-5p, hsa-mir-181B-5p, hsa-mir-30b-5p, hsa-mir-155-5p, hsa-mir-146b-5p, hsa-mir-21-3p, hsa-mir-26a-2

hsa-mir-30a-3p, hsa-mir-181a-5p, hsa-mir-181B-5p, hsa-mir-210-3p, hsa-mir-185-5p, hsa-mir-155-5p, hsa-mir-146b-5p, hsa-mir-424-3p, hsa-mir-27a-3p, hsa-mir-199a-5p, hsa-mir-199a-3p, hsa-mir-21-3p

hsa-mir-181a-5p, hsa-mir-146b-5p, hsa-mir-7-5p, hsa-mir-210-3p, hsa-mir-181b-5p, hsa-mir-155-5p, hsa-mir-424-3p, hsa-mir-125a-5p, hsa-mir-34a-5p, hsa-mir-221-5p, hsa-mir-221-3p, hsa-mir-30b-5p, hsa-mir-199a-5p, hsa-mir-199a-3p, hsa-mir-27a-3p, hsa-mir-21-3p

Positive Regulation of
Inflammatory Response
(GO:0050729)

Negative Regulation of
Inflammatory Response
(GO:0050728)

Adaptive Immune
Response
(GO:0002250)

Innate Immune
Response
(GO:0045087)

(A) **(B)** **(C)** **(D)**